PI3K inhibitors have been widely approved in the treatment of indolent non-Hodgkin lymphomas, mainly Follicular lymphoma (FL), in case of disease relapse or refractoriness to anti-CD20 agents, alkylators, or purine analogues. This evidence concerns the gene PIK3CD and non-Hodgkin lymphoma.